Solid Biosciences Inc. Payments of Stock Issuance Costs
Solid Biosciences Inc. (SLDB) reported Payments of Stock Issuance Costs of $13.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-06
- Solid Biosciences Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $754.00K.
- Solid Biosciences Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $12.89M.
- Solid Biosciences Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- Solid Biosciences Inc. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00.
- Solid Biosciences Inc. payments of stock issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Solid Biosciences Inc. payments of stock issuance costs for fiscal 2024 was $5.11M.
- Solid Biosciences Inc. payments of stock issuance costs for fiscal 2023 was $0.00.
- Solid Biosciences Inc. payments of stock issuance costs for fiscal 2020 was $3.79M, a 80.30% increase from fiscal 2019.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $754.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $13.64M 10-Q · filed 2026-08-06 | $13.64M derived: sum of 3 quarters · filed 2026-08-06 | $13.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $12.89M 10-Q · filed 2026-05-12 | $12.89M derived: sum of 2 quarters · filed 2026-05-12 | $12.89M derived: sum of 3 quarters · filed 2026-05-12 | $12.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 10-K · filed 2026-03-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-03 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $286.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $286.00K derived: sum of 3 quarters · filed 2026-03-19 | $5.11M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $286.00K derived: sum of 2 quarters · filed 2025-11-03 | $5.11M 10-Q · filed 2025-11-03 | $5.11M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $286.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $5.11M 10-Q · filed 2025-08-12 | $5.11M derived: sum of 3 quarters · filed 2025-08-12 | $5.11M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $4.83M 10-Q · filed 2025-05-15 | $4.83M derived: sum of 2 quarters · filed 2025-05-15 | $4.83M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2020-12-31 | $3.79M 10-K · filed 2023-03-23 | |||
| 2019-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $2.10M 10-K · filed 2022-03-14 | ||
| 2019-09-30 | $1.81M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $0.00 derived: sum of 2 quarters · filed 2021-03-15 | $193.00K derived: sum of 3 quarters · filed 2021-03-15 | $2.17M 10-K · filed 2021-03-15 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $193.00K derived: sum of 2 quarters · filed 2019-11-12 | $2.17M 10-Q · filed 2019-11-12 | $3.41M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $2.17M 10-Q · filed 2019-08-14 | $3.41M derived: sum of 3 quarters · filed 2020-03-12 | $4.36M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $1.98M 10-Q · filed 2019-05-13 | $3.22M derived: sum of 2 quarters · filed 2020-03-12 | $4.16M derived: sum of 3 quarters · filed 2020-03-12 | $4.22M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $2.19M derived: sum of 2 quarters · filed 2020-03-12 | $2.25M derived: sum of 3 quarters · filed 2020-03-12 | $2.42M 10-K · filed 2020-03-12 |
| 2017-09-30 | $943.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $1.00M derived: sum of 2 quarters · filed 2018-11-13 | $1.18M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $236.00K 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $178.00K 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |